The risk factors for post-polypectomy bleeding and establishment of a risk-scoring model for small colorectal polyps (<1.5cm) in an ambulatory surgery center: a retrospective analysis

Tiantian Lei  
Sichuan University West China Hospital

Hailin Yan  
Sichuan University West China Hospital

Qing Lu  
Sichuan University West China Hospital

Yilan Wang  
Sichuan University West China Hospital

Hongsheng Ma  
Sichuan University West China Hospital

Jinlin Yang  (✉️ mouse-577@163.com)  
Sichuan University West China Hospital

Research article

Keywords: factors; PPB; scoring model; ambulatory surgery

DOI: https://doi.org/10.21203/rs.2.15796/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: As one of the most common complications of colonoscopy, the risk factors of post-polypectomy bleeding (PPB) has been rarely explored in an ambulatory surgery unit. We aim to develop a risk-scoring model to predict the risk of PPB for small colorectal polyps (<1.5 cm) in an ambulatory surgery unit.

Methods: The patients with single small colorectal polyps (<1.5 cm) who underwent endoscopic polypectomy in the Ambulatory Surgery Center of our hospital between January 2014 and June 2017 were included and retrospectively reviewed. We analyzed patient's clinical characteristics, morphological and pathological characteristics of polyps, polypectomy techniques, and the occurrence of PPB. Risk factors of PPB were identified with a multivariable logistic regression model. In addition, a risk-scoring system was developed and validated eventually.

Results: Among the 771 patients enrolled, 26 (3.4%) patients suffered PPB. The male gender, elderly age (≥ 60 years), using hot biopsy forceps as polypectomy technique adenoma in histopathology, complicated with hypertension, use of anticoagulant or antiplatelet agents, and early excessive activities significantly increased the risk of PPB (P < 0.05) as indicated by the results of multivariable logistic regression analysis. The area under the ROC curve (AUC) in the model group (0.890) and validation group (0.924) indicated that the risk-scoring model could predict the occurrence of PPB effectively.

Conclusions: This risk-scoring method may help to predict the risk of PPB for small colorectal polyps, fit well in the Ambulatory Surgery Center, and provide a new approach to help reduce the incidence of hemorrhage after colorectal polypectomy.

Trial registration: This study was retrospectively registered and approved by the Ethics Committee of West China Hospital of Sichuan University (IRB number: ChiCTR1800020201).

Background

Colorectal polypectomy is currently considered an effective strategy to reduce the incidence of colorectal cancer. Colonoscopic polypectomy is routinely believed to be a safe procedure; however post-polypectomy bleeding (PPB), which is one of the most frequent complications after endoscopic operations, may cause serious problems and adverse consequences.

Ambulatory surgery provides high quality and efficient care for a wide variety of surgical procedures. During the last decades, ambulatory surgery has grown rapidly and now accounts for the majority of operations performed in endoscopic therapy in China. On the other hand, the safety of day surgery must be emphasized. Thus, the safety of colonoscopic polypectomy in the Day Surgery Unit should be taken into account when discussing cost-effective economy and rapid recovery.
Previous studies mostly involved multiple or large colorectal polyps among inpatients. The patients underwent the polypectomy in the Day Surgery Unit and were characterized with smaller size polyps (≤1.5 cm), younger population and limited complications. They were encouraged to perform appropriate activities and diets after the polypectomy as soon as possible. Consequently, it is essential to balance the safety and efficiency via investigating the risk factors of PPB based on day surgery. Furthermore, it would be valuable to establish a risk-scoring model of ambulatory surgery to predict the occurrence of PPB, as little research has described it ever before.

Methods

Patients

The records of 2,744 patients who presented with colorectal polyps and underwent an endoscopic colorectal polypectomy in the Day Surgery Unit of West China Hospital, Sichuan University from January 2014 to June 2017 (total 42 months) were reviewed and analyzed. Inclusion criteria were (1) patients with single colorectal polyp, (2) a polyp size ≤ 15mm and (3) aged between 14 and 80 years old. In addition, (4) all patients were required to meet the American Association of Anesthesiologists (ASA) score of less than 3. Patients (i) with multiple-colorectal polyps, (ii) a laterally spreading tumor (LST), and (iii) a history of inflammatory bowel disease (IBD) or (iv) hemorrhagic disease were excluded. We also excluded (v) the cases of carcinoma which were pathologically confirmed after polypectomy, as well as (vi) the patients with incomplete clinical data. Consequently, 771 patients were ultimately enrolled. We divided the patients into bleeding and non-bleeding groups according to the occurrence of PPB. A total of another 198 patients with colorectal polyps were included in the Day Surgery Unit from July 2017 to December 2017 as a validation cohort. The study flow is shown in Figure 1. Complete medical records of the patient-related characteristics, polyp-related characteristics, and polypectomy techniques, as well as the use of prophylactic clips during the endoscopic procedure, were collected. This study was approved by the Ethics Committee of West China Hospital of Sichuan University (IRB number: ChiCTR1800020201).

Endoscopic Colorectal Polypectomy

Written consent was obtained before the operation. If anticoagulant or antiplatelet agents were needed, such as aspirin, warfarin or clopidogrel, they were required to discontinue these at least 5 days before the operation. Endoscopic colorectal polypectomy was performed by electronic endoscopes (JIF-H260Z; Olympus Optical Co, Ltd, Tokyo, Japan) by experienced endoscopists who had performed at least 500 cases of endoscopic polypectomies. We routinely applied argon plasma coagulation (APC) (ERBE Co, Ltd, Germany) and hot biopsy forceps (HBF) (Stericlín Co, Ltd, Germany) for diminutive polyps (d≤5mm) and small polyps (d≤10mm), while larger sessile polyps (10mm≤d≤15mm) were resected by endoscopic mucosal resection (EMR) and pedunculated polyps were removed by snares (SAS–1-S; COOK Co, Ltd, US). Hemostatic clips were selected when bleeding occurred during the operation or to prevent delayed hemorrhage.
Post-polypectomy Bleeding

In our study, PPB was confirmed with the presence of hematochezia, while melena or hemorrhoids were excluded. We also defined early PPB (EPPB) as hemorrhage within 24 hours of the colorectal polypectomy and delayed PPB (DPPB) was referred to as hemorrhage during 24 hours to 4 weeks after the endoscopic operation. Follow-up telephone calls within 4 weeks were conducted regularly on the 2nd day, 7th day, 14th day, and 28th day after discharge from the hospital.

Patient-related Factors

We collected the patients demographic characteristics, including gender and age. In addition, the factors of antithrombotic agents, history of smoking and alcohol consumption, postoperative activities and diet were compared between two groups. Smoking was defined as a continuous or cumulative smoking habit for 6 months or more in one's lifetime. Alcohol consumption referred to drinking 10 grams per day on average. Comorbidities of hypertension, diabetes mellitus, cerebrovascular disease, coronary heart disease, hyperlipidemia, chronic obstructive pulmonary disease (COPD), and rheumatoid diseases were also reviewed. Improper postoperative activities referred to intense exercise or heavy physical activity within the 2 weeks after endoscopic operations. Inappropriate diet was defined as starting oral feeding within 6 hours or having spicy or greasy food within 1 week after the operation.

Polyp-related Factors

The size, location, gross morphology and the histopathology of the colorectal polyps were carefully documented. An open-biopsy forcep of 6mm was used as standard to measure the polyp size. The polyp location contained ascending colon (cecum was included), transverse colon (hepatic flexure and splenic flexure were included), descending colon, sigmoid colon, and rectum. The morphology of the polyp was categorized into four types (Yamada Ⅰ, Yamada Ⅱ, Yamada Ⅲ, and Yamada Ⅳ) according to the criteria of Japanese Yamada Classification. Polyps were classified histopathologically as adenomatous (tubular, tubulovillous, and villous) or hyperplastic, inflammatory, and others (hamartomatous, retentional, etc.).

Statistical Analysis

All statistical analysis were performed with SPSS software version 24.0 (SPSS Institute, Chicago, IL). Categorical variables were compared with the Fisher exact test or the \( \chi^2 \) test. Continuous variables were compared with either the unpaired Student t test or the Mann-Whitney U test. The odds ratios for delayed post-polypectomy hemorrhage were calculated by unconditional logistic regression. In addition, multivariable logistic regression analysis was performed to identify independent variables associated with PPB. The score-based prediction rule was generated from the new logistic regression equations by using a regression coefficient-based scoring method []. The total score for each patient represented the
sum of the score for each independent risk factor. The calibration was evaluated with the Hosmer-Lemeshow (H-L) goodness-of-fit test. To evaluate the predictive performance of the scoring model, the receiver operating characteristic (ROC) curve and the area under the ROC (AUC) were adopted. An AUC of 1.0 indicated perfect concordance, while an AUC of 0.5 indicated no relationship. Meanwhile, external validation of the model was performed by measuring the discriminatory ability with AUC.

**Results**

**Baseline Characteristics**

During the study period, a total of 771 single-polyp patients underwent colorectal polypectomy with 771 polyps being completely removed. The baseline characteristics of the patients are shown in Table 1. Males counted for 42.2% (325/771) of this cohort and the median age was 44 (40, 61) years old. The colorectal polyps were located frequently in the left-half colon which contained the descending colon (197/771, 25.6%) and sigmoid colon (203/771, 26.3%). The median polyp size was 0.6 (0.5, 0.8) cm. In addition, we adopted HBF (227/771, 29.4%) and EMR (306/771, 39.7%) more frequently than APC (147/771, 19.1%) and snare (91/771, 11.8%) to resect the lesions. Furthermore, 76 (9.9%) patients had prophylactic clips applied to prevent delayed hemorrhage during the procedure. Among this cohort, 12 (1.6%) patients had a long-term history of anticoagulant/antiplatelet therapy in spite of 5-days withdrawal before the colorectal polypectomy. Moreover, 124 (16.1%) patients were investigated to have intense postoperative activities, and 72 (9.3%) patients were found to have an inappropriate postoperative diet.

Overall, PPB occurred in 26 patients (3.4%) while DPPB developed in 23 patients. PPB appeared to take placed as on day 7 (5, 10) after the polypectomy, of which 15 (57.7%) patients had received endoscopic hemostatic procedures. Only one patient underwent a blood transfusion, and none required selective arterial embolization or surgery. The results showed that gender, age, early postoperative activity, and hypertension were statistically different between the bleeding and non-bleeding groups (P<0.05).

**Risk Factors of PPB**

As revealed in the univariate analyses, the gender and age of the patients, complication of hypertension, history of alcohol, and early postoperative activity differed significantly (P<0.05) between the bleeding and non-bleeding groups. In terms of multivariate logistic regression analysis, gender of male, age older than 60, histopathology of adenomatous polyps, polypectomy technique of HBF, complication of hypertension, use of anticoagulant/antiplatelet agents, and early excessive postoperative activities appeared to be the independent risk factors, which were associated with PPB, whereas location, size, morphology, applicaton of prophylactic clips, other comorbidities, history of smoking or alcohol, as well as inappropriate diet were not statistically significant (Table 2).
Establishment of the Risk-Scoring Model for Predicting Colorectal PPB

Risk factors that represented statistical significance were utilized to develop the risk-scoring model to predict the possibility of colorectal PPB. The $\beta$ coefficients of variables with $p<0.05$ in the multivariate logistic regression analysis were used to generate the model. Point values were assigned to the identified independent risk factors as follows: male (OR: 7.295, 1 point), aged beyond 60 years (OR: 10.615, 1 point), adenoma (OR: 4.931, 1 point), HBF (OR: 5.659, 1 point), early intense activity (OR: 9.601, 1 points), hypertension (OR: 6.827, 1 point), and anticoagulant or antiplatelet drugs (OR: 51.435, 2 points) which was revealed in Table 3.

Risk stratification based on the total points contains the low risk group (0–2 points, 0.5%), intermediate risk group (3–4 points, 8.1%), and high risk group (> 4 points, 50.0%). With regard to the 771 patients who underwent colorectal polyp resection, the risk scores ranged from 0 to 6 (Table 4(A)). The risk for PPB increased from 1.0% to 100.0% along with the total risk score of each patient. Subsequently, the risk score was categorized as low risk (0–2 point), intermediate risk (3–4 points), and high risk (>4 points) for PPB. As a result, the rates of PPB for each risk category were 0.5%, 8.1%, and 50.0%, respectively (Table 4(B)), with a significantly increasing trend of risk from the low to high risk groups. The predictive accuracy of the risk score for PPB was 0.890 (95%CI, 0.806–0.960) measured by AUC (Figure 2). In addition, our prediction model calibrated well with the Hosmer-Lemeshow goodness-of-fit test ($\chi^2 = 1.030, P = 0.794$).

External Validation of the Risk Scoring Model

A total of another 198 patients with colorectal polyps were included in the Day Surgery Unit from July 2017 to December 2017 as an external validation cohort. The percentage of the risk for PPB in each calculated score and AUC were 0.924 in the validation dataset (Figure 2).

Discussion

The current study of a large cohort established a novel, simple-to-use risk-scoring system of colorectal PPB, which comprises various aspects of clinical features. Our finding is one of the largest cohorts to investigate the frequent but serious adverse event of PPB in the Ambulatory Surgery Center. We have dedicated to risk stratification based on these significant clinical risk factors, and established a predictive model that can be applied to the safety of polypectomy in the Ambulatory Surgery Center.

We found that advanced age and hypertension in patients were independent risk factors for PPB. In recent years, although patients with colorectal polyps tended to be younger, PPB continued to occur in the elder patients because of poor vascular compliance [1,6]. In addition, the various cardiovascular and cerebrovascular diseases associated with advanced age and hypertension might bring about impaired blood vessel wall and abnormal coagulation function [7].
Based on the findings of previous studies, large size was a significant polyp-related factor that has been unequivocally proven to increase the risk of delayed bleeding. Buddingh KT [3] thought that the risk increased by 13% for every 1mm increase in polyp diameter (OR:1.13, 95%CI 1.05–1.20, P<0.001). However, we did not come to a similar conclusion as we believe that a limited colorectal polyp size of 15mm would not play such a vital role. The significant associations between colorectal adenomatous polyps and postoperative bleeding in our study, in particular, have been previously corroborated [5]. Adenomatous polyps, reported by Uno Y [], had more blood vessels exposed upon removal of the polyp, which was probably related to PPB.

Moreover, we also demonstrated that HBF had an obviously higher risk of PPB compared with EMR or snare excision. Traditional HBF is routinely performed in China for polypectomy while western application is rare. HBF technique involves the use of insulated monopolar electrocoagulating forceps to simultaneously biopsy and electrocoagulate the tissue []. Recently, Panteris V [] aroused a debatable topic associated with the abandonment of HBF for polypectomy of diminutive or small colorectal polyps. The new recommendation released by European Society of Gastrointestinal Endoscopy (ESGE) [] is expected to against their use of HBF based on the GRADE system of clinical evidence. The reasons include unacceptably high risks of adverse events such as deep thermal injury and delayed bleeding, as well as incomplete resection and inadequate tissue sampling for histology, in comparison with snare excision []. In addition, the placement of prophylactic clips had no benefit on reducing the incidence of PPB in the light of our findings.

According to risk stratification of endoscopic procedures, endoscopic polypectomy is defined as high risk procedure. What is more, for patients receiving anticoagulation or antiplatelet therapy, the risk of haemorrhage sharply increases. The challenge is to weigh the benefits against risks of thromboembolism and PPB. We found that the use of anticoagulant or antiplatelet drugs led to a higher risk of bleeding, which was consistent with several reported studies [,]. In particular, bridge anticoagulation is necessary in patients with high thromboembolic risks who are undergoing polypectomy []. The recent BRIDGE trial, which showed that bridging anticoagulation is associated with a significantly higher risk of hemorrhage []. Regrettably, we did not classify the categories of antithrombotic drugs, such as warfarin, aspirin or clopidogrel. In future, we may pay close attention to the potential risk of PPB in patients receiving antithrombotic therapy although these drugs has been strictly discontinued and restarted. We consider that it is necessary to delay discharge or extend the follow-up time to ensure the safety of these special patients who received colorectal polypectomy in ambulatory surgery unit.

We also demonstrated that intense exercise or heavy physical activity within 2 weeks after polypectomy was associated with delayed bleeding. In clinical practice, we emphasize the importance of post-polypectomy recovery at home, especially the guidance of discharge instructions within 7 days. We advocate the efficient and safe hospital clinical pathway of day surgery, meanwhile greater emphasis needs to be placed on standardized discharge criteria and high quality discharge follow-up based on clinical risk assessment.
Although our study provides a reliable risk-scoring model of PPB, it has several limitations. An inherent potential bias was inevitable as the study is retrospective despite partial data being collected prospectively. Furthermore, bridge anticoagulation and the time to restart the antithrombotic therapy should be considered as significant variables associated with PPB for a more complete risk-scoring system.

Conclusions

In summary, this was the first study to clarify the risk factors of PPB in the certain populaton of ambulatory surgery. We aimed to promote the development and growth of high quality ambulatory surgery. To this end, this risk-scoring model has resulted in the founding of new association of ambulatory surgery and endoscopic therapy. The significance of this study is that a predictive model was developed, which could provide more valuable clinical information for making a better decision about revising the access criteria and follow-up after discharge. Furthermore, high efficiency, remarkable safety and cost reduction of ambulatory surgery have been improving the access of the general population to utilize of endoscopic treatment with colorectal polyps.

Abbreviations

PPB post-polypectomy bleeding
ROC receiver operating characteristic
AUC area under the ROC curve
HBF hot biopsy forceps
LST laterally spreading tumor
IBD inflammatory bowel disease
APC argon plasma coagulation
EMR endoscopic mucosal resection
EPPB early PPB
DPPB delayed PPB
COPD chronic obstructive pulmonary disease
H-L Hosmer-Lemeshow

Declarations
Ethics approval and consent to participate

This study was retrospectively registered and approved by the Ethics Committee of West China Hospital of Sichuan University (IRB number: ChiCTR1800020201). Consent to participate was waived due to the fact that this is a retrospectively study with no risk to participants, where the research will not affect the rights or welfare of the participants.

Consent for publication

Not applicable.

Availability of data and materials

The datasets analysed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

Competing interests

Tiantian Lei, Hailin Yan, Qing Lu, Yilan Wang, Hongsheng Ma and Jinlin Yang have no competing interest or financial ties to disclose.

Funding

This study was supported by the Science and Technology Department of Sichuan Province for Scientific Research in China: Study on Safety Management in Day Surgery Center based on Quality Evaluation Model (Nos.2018ZR0243). This funding funded our expenses for language modification of the article.

Authors’ Contributions

JY and HM designed the research. TL analyzed the data and wrote the paper. TL, HY, YW, QL performed the research. TL, HY and QL performed the follow-ups. HM and JY revised this manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Authors’ Information
Tiantian Lei, Department of Day Surgery, West China hospital of Sichuan University, 37 Guoxue Road, Chengdu, 610041, Sichuan, China, Email: 562496525@qq.com.

Hailin Yan, Department of Gastroenterology, West China Hospital of Sichuan University, No.37 Guo Xue Alley, Chengdu, 610041, Sichuan Province, China, Email: yanhailin1994@qq.com.

Qing Lu, Department of Gastroenterology, West China Hospital of Sichuan University, No.37 Guo Xue Alley, Chengdu, 610041, Sichuan Province, China, Email: 1343830687@qq.com.

Yilan Wang, Department of Gastroenterology, West China Hospital of Sichuan University, No.37 Guo Xue Alley, Chengdu, 610041, Sichuan Province, China, Email: 316691968@qq.com.

Hongsheng Ma, Department of Day Surgery, West China hospital of Sichuan University, 37 Guoxue Road, Chengdu, 610041, Sichuan, China, Email: mahongsheng63@163.com

Jinlin Yang, Department of Gastroenterology, West China Hospital of Sichuan University, No.37 Guo Xue Alley, Chengdu, 610041, Sichuan Province, China, Email: mouse–577@163.com

Reference

1. Moons KG, Harrell FE, Steyerberg EW. Should scoring rules be based on odds ratios or regression coefficients? Journal of Clinical Epidemiology. 2002 Oct; 55(10): 1054-5. doi: 10.1016/S0895-4356(02)00453-5

2. Sawhney MS, Salfiti N, Nelson DB, et al. Risk factors for severe delayed postpolypectomy bleeding. Endoscopy. 2008 Feb; 40(2): 115–9. doi: 10.1055/s-2007-966959.

3. Buddingh KT, Herngreen T, Haringsma J, et al. Location in the right hemi-colon is an independent risk factor for delayed postpolypectomy hemorrhage: a multi-center case-control study. American Journal of Gastroenterology. 2011 Jun; 106(6): 1119–24. doi: 10.1038/ajg.2010.507. Epub 2011 Jan 25.

4. Choung BS, Kim SH, Ahn DS, et al. Incidence and risk factors of delayed postpolypectomy bleeding: a retrospective cohort study. Journal of Clinical Gastroenterology. 2014 Oct; 48(9):784–9. doi: 10.1097/MCG.0000000000000027.

5. Amato A, Radaelli F, Dinelli M, et al. Early and delayed complications of polypectomy in a community setting: The SPoC prospective multicentre trial. Digestive and Liver Disease. official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2016 Jan; 48(1): 43-8. doi: 10.1016/j.dld.2015.09.007. Epub 2015 Sep 28.

6. Consolo P, Luigiano C, Strangio G, et al. Efficacy, risk factors and complications of endoscopic polypectomy: ten year experience at a single center. World Journal of Gastroenterology. 2008 Apr 21; 14(15): 2364-9. doi: 10.3748/wjg.14.2364

7. Uno Y, Satoh K, Tuji K, et al. Endoscopic ligation by means of clip and detachable snare for management of colonic postpolypectomy hemorrhage. Gastrointestinal Endoscopy. 1999 Jan; 49(1): 113-5. doi: 10.1016/S0016-5107(99)70458-X
8. Wadas DD, Sanowski RA. Complications of the hot biopsy forceps technique. Gastrointestinal Endoscopy. 1988 Jan-Feb;34(1):32-7. doi: 10.1016/S0016-5107(88)71226-2

9. Panteris V, Vezakis A, Triantafillidis JK. Should hot biopsy forceps be abandoned for polypectomy of diminutive colorectal polyps? World Journal of Gastroenterology. 2018 Apr 14; 24(14): 1579-82. doi: 10.3748/wjg.v24.i14.1579.

10. Ferlitsch M, Moss A, Hassan C, et al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2017 Mar; 49(3): 270-97. doi: 10.1055/s-0043-102569. Epub 2017 Feb 17.

11. Moss A, Nalankilli K. Standardisation of Polypectomy Technique. Best Practice & Research. Clinical Gastroenterology. 2017 Aug; 31(4):447-53. doi: 10.1016/j.bpg.2017.05.007. Epub 2017 Jun 6.

12. Pigò F, Bertani H, Manno M, et al. Postpolypectomy Bleeding Is Related to Polyp Size and Heparin Use. Colonical Endoscopy. 2017 May; 50(3): 287-92. doi: 10.5946/ce.2016.126. Epub 2017 Feb 9.

13. Duk Hwan Kim. Prediction and Prevention of Postpolypectomy Bleeding: Necessity of a Different Approach for Patients Using Antithrombotic Agents. Clinical Endoscopy. 2017 May; 50(3):217-8. doi: 10.5946/ce.2017.056. Epub 2017 May 31.

14. Lin D, Soetikno RM, McQuaid K, et al. Risk factors for postpolypectomy bleeding in patients receiving anticoagulation or antiplatelet medications. Gastrointestinal Endoscopy. 2018 Apr; 87(4):1106-13. doi: 10.1016/j.gie.2017.11.024. Epub 2017 Dec 6.

15. ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointestinal Endoscopy. 2016 Jan; 83(1): 3-16. doi: 10.1016/j.gie.2015.09.035. Epub 2015 Nov 24.

16. Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy. 2016 Apr; 48(4): c1. doi: 10.1055/s-0042-122686. Epub 2017 Jan 23.

17. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. The New England Journal of Medicine. 2015 Aug 27; 373(9): 823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22.

Tables

Table 1. Baseline characteristics of patients and univariate analysis of risk factors for PPB
| Variables                     | Total N=771 | Non-bleeding N=745 (%) | Bleeding N=26 (%) | P-value |
|-------------------------------|-------------|------------------------|-------------------|---------|
| **Patient-related factors**   |             |                        |                   |         |
| gender*                       |             |                        |                   |         |
| Female                        | 446         | 441 (59.2)             | 5 (19.2)          | 0.001   |
| Male                          | 325         | 304 (40.8)             | 21 (80.8)         |         |
| Age                           | 44 (40.61)  |                        |                   | 0.001   |
| **Polyp-related factors**     |             |                        |                   |         |
| Location                      |             |                        |                   |         |
| Transverse colon \(^a\)       | 121         | 117 (15.7)             | 4 (15.4)          | 0.64    |
| Descending colon \(^b\)       | 197         | 186 (25.0)             | 11 (42.3)         |         |
| Ascending colon               | 97          | 96 (12.9)              | 1 (3.8)           |         |
| Sigmoid colon                 | 203         | 197 (26.4)             | 6 (23.1)          |         |
| Rectum                        | 153         | 149 (20.0)             | 4 (15.4)          |         |
| **size^†**                    | 0.6 (0.5,0.8)|                      |                   | 0.513   |
| morphology                    |             |                        |                   |         |
| Yamada type \(^γ\)           | 236         | 225 (30.2)             | 11 (42.3)         | 0.554   |
| Yamada type \(^δ\)           | 343         | 336 (45.1)             | 7 (26.9)          |         |
| Yamada type \(^ζ\)           | 149         | 143 (19.2)             | 6 (23.1)          |         |
| Yamada type \(^η\)           | 43          | 41 (5.5)               | 2 (7.7)           |         |
| Histopathology                |             |                        |                   |         |
| Inflammatory polyps           | 168         | 165 (22.1)             | 3 (11.5)          | 0.153   |
| Hyperplastic polyps           | 177         | 173 (23.2)             | 4 (15.4)          |         |
| Adenomatous polyps            | 367         | 349 (46.8)             | 18 (69.2)         |         |
| Others^‡                      | 59          | 58 (7.8)               | 1 (3.8)           |         |
| **Polypectomy technique**     |             |                        |                   |         |
| APC                           | 147         | 147 (19.7)             | 0 (0.0)           |         |
| Hot biopsy forceps            | 227         | 208 (27.9)             | 19 (73.1)         |         |
| Snare                         | 91          | 88 (11.8)              | 3 (11.5)          |         |
| EMR                           | 306         | 302 (40.5)             | 4 (15.4)          |         |
| **Clips**                     |             |                        |                   |         |
| Yes                           | 76          | 75 (10.1)              | 1 (3.8)           | 0.477   |
| No                            | 695         | 670 (89.9)             | 25 (96.2)         |         |
| **Comorbidities**             |             |                        |                   |         |
| Hypertension                  |             |                        |                   |         |
| Yes                           | 129         | 116 (15.6)             | 13 (50.0)         | 0.001   |
| No                            | 642         | 629 (84.4)             | 13 (50.0)         |         |
| Diabetes mellitus             |             |                        |                   |         |
| Yes                           | 42          | 41 (5.5)               | 1 (3.8)           | 0.999   |
| No                            | 729         | 704 (94.5)             | 25 (96.2)         |         |
| Cerebrovascular disease       |             |                        |                   |         |
| Yes                           | 8           | 7 (0.9)                | 1 (3.8)           | 0.999   |
| No                            | 763         | 738 (98.9)             | 25 (100.0)        |         |
| Coronary heart disease        |             |                        |                   |         |
| Yes                           | 27          | 26 (3.5)               | 1 (3.8)           | 0.999   |
| No                            | 744         | 719 (96.5)             | 25 (96.2)         |         |
| Hyperlipidemia                |             |                        |                   |         |
| risk factor                        | Yes  | No   |
|----------------------------------|------|------|
|                                 |      |      |
|                                 |      |      |
| Yes                             | 64   | 707  |
| COPD                            | 10   | 761  |
| Rheumatoid diseases             | 13   | 758  |
| Anticoagulant/anti-platelet drugs| 12   | 759  |
| Smoking                         | 116  | 655  |
| Alcohol                         | 116  | 655  |
| Improper activity               | 124  | 647  |
| Inappropriate diet              | 72   | 699  |
|                                 | 62 (8.3) | 683 (91.7) | 2 (7.7) | 24 (92.3) |
|                                 | 10 (1.3) | 735 (98.7) | 0 (0.0) | 26 (100.0) |
|                                 | 13 (1.7) | 732 (98.3) | 0 (0.0) | 26 (100.0) |
|                                 | 11 (1.5) | 734 (98.5) | 1 (3.8) | 25 (96.2) |
|                                 | 109 (14.6) | 636 (85.4) | 7 (26.9) | 19 (73.1) |
|                                 | 108 (14.5) | 637 (85.5) | 8 (30.8) | 18 (69.2) |
|                                 | 112 (15.0) | 633 (85.0) | 12 (46.2) | 14 (53.8) |
|                                 | 71 (9.5) | 674 (90.5) | 1 (3.8) | 25 (96.2) |

**Table 2. Multivariate Logistic Regression Analysis of risk factors for PPB**
| Variables                        | No. of patients | No. of PPB | OR (95%CI)     | P-value |
|---------------------------------|----------------|-----------|----------------|---------|
| **Patient-related factors**     |                |           |                |         |
| **gender***                     |                |           |                |         |
| Female                          | 446            | 5         | 1 (Reference)  |         |
| Male                            | 325            | 21        | 7.295 (2.087-25.498) | 0.002   |
| **age†**                        |                |           |                |         |
| n<40                            | 174            | 3         | 1 (Reference)  |         |
| 40≤ n<60                        | 386            | 7         | 1.315 (0.213-8.128) | 0.768   |
| n ≥60                           | 211            | 16        | 10.615 (1.684-66.927) | 0.012   |
| **Polyp-related factors**       |                |           |                |         |
| **Location**                    |                |           |                |         |
| Transverse colon #              | 121            | 4         | 1 (Reference)  |         |
| Descending colon                | 197            | 11        | 2.707 (0.564-12.985) | 0.213   |
| Ascending colon                 | 97             | 1         | 0.106 (0.006-1.913) | 0.128   |
| Sigmoid colon                   | 203            | 6         | 1.369 (0.246-7.622) | 0.720   |
| rectum                          | 153            | 4         | 0.996 (0.171-5.793) | 0.996   |
| **size‡**                       |                |           |                |         |
| d<0.5cm                         | 167            | 5         | 1 (Reference)  |         |
| 0.5≤d<1cm                       | 527            | 19        | 1.126 (0.254-4.985) | 0.876   |
| d≥1cm                           | 77             | 2         | 2.298 (0.201-26.289) | 0.503   |
| **morphology**                  |                |           |                |         |
| Yamada type Ⅰ                   | 236            | 11        | 1 (Reference)  |         |
| Yamada type Ⅱ                   | 343            | 7         | 0.315 (0.081-1.228) | 0.096   |
| Yamada type Ⅲ                   | 149            | 6         | 0.779 (0.159-3.812) | 0.758   |
| Yamada type Ⅳ                   | 43             | 2         | 1.479 (0.109-20.073) | 0.769   |
| **Histopathology**              |                |           |                |         |
| Inflammatory polyps             | 167            | 3         | 1 (Reference)  |         |
| Hyperplastic polyps             | 177            | 4         | 1.767 (0.279-11.198) | 0.546   |
| Adenomatous polyps              | 368            | 18        | 4.931 (1.056-23.026) | 0.042   |
| Others‡                         | 59             | 1         | 2.223 (0.160-30.799) | 0.552   |
| **Polypectomy technique**       |                |           |                |         |
| EMR                             | 306            | 4         | 1 (Reference)  |         |
| APC                             | 147            | 0         | 0.000 (0.000-999.99) | 0.995   |
| Hot biopsy forceps              | 227            | 19        | 5.659 (1.239-25.843) | 0.025   |
| Snare                           | 91             | 3         | 2.149 (0.349-13.244) | 0.410   |
| Clips                           | 76             | 1         | 0.081 (0.002-2.850) | 0.166   |
| **Comorbidities**               |                |           |                |         |
| Hypertension                    | 129            | 13        | 6.827 (2.136-0.001) |         |
| Risk factors                  | Male | P value | β coefficient | Points |
|------------------------------|------|---------|---------------|--------|
| Diabetes mellitus            | 21.817 | 0.002   | 1.987         | 1      |
| Cerebrovascular disease      | 2.932 (0.262-32.791) | 0.012   | 2.362         | 1      |
| Coronary heart disease       | 0.748 (0.020-28.671) | 0.042   | 1.596         | 1      |
| Hyperlipidemia               | 1.288 (0.038-43.590) | 0.025   | 1.733         | 1      |
| COPD                         | 0.721 (0.105-4.965)  | 0.44    | 0.044         | 0.044  |
| Rheumatoid diseases          | 0.000 (0.000-999.99) | 0.72     | 0.036         | 0.036  |
| Anticoagulant/antiplatelet drugs | 51.435 (1.119-999.99) | 0.001   | 2.632         | 2      |
| smoking                      | 2.353 (0.684-8.091)  | 1.342   | 0.644         | 0.644  |
| Alcohol                      | 1.342 (0.386-4.670)  | 0.007   | 0.071         | 0.071  |
| Improper activity            | 9.601 (2.997-30.760) | 0.001   | 2.632         | 2      |
| Inappropriate diet           | 0.234 (0.022-2.464)  | 0.044   | 0.044         | 0.044  |

OR, Odds ratio; CI, confidence interval

**Table 3. Establishment of the risk-scoring model for PPB.**

**Table 4. Distribution of risk scores and risk classification for PPB in the development cohort**
(A) Total points & No. of patients (n=771) & No. of PPB (n=26) & Rate of PPB(%) \\
0 & 97 & 1 & 1.0 \\
1 & 218 & 0 & 0.0 \\
2 & 225 & 2 & 0.9 \\
3 & 142 & 5 & 3.5 \\
4 & 43 & 10 & 23.3 \\
5 & 14 & 6 & 42.9 \\
6 & 2 & 2 & 100.0 \\

(B) Risk category & Total points & No. of patients (n=771) & No. of PPB (n=26) & Rate of PPB(%) \\
low risk & 0-2 & 570 & 3 & 0.5 \\
intermediate risk & 3-4 & 185 & 15 & 8.1 \\
high risk & >4 & 16 & 8 & 50.0 \\

Figures
Patients underwent colorectal polypectomy in day surgery center during Jan 2014 and June 2017. 
n=2744

1973 patients were excluded:  
(i) multiple-colorectal polyps, n = 1821  
(ii) LST, n = 24  
(iii) history of IBD, n=12  
(iv) hemorrhagic disease, n=81  
(v) pathologically confirmed carcinoma, n=5  
(vi) incomplete clinical data, n=30

771 patients were ultimately enrolled.  
n=771

26 patients developed PPB  
745 patients without PPB

Patients underwent colorectal polypectomy during June 2017 to December 2017 as an external validation cohort.  
n=198

8 patients with PPB  
190 patients without PPB

Figure 1  
Study flow chart.
Figure 2

ROC curve and ROC-AUC in the model group and validation group.